DGAP-News: Annual Shareholder's Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): AGM/EGM
Annual Shareholder's Meeting of Cytos Biotechnology Ltd: Shareholders
approve all resolutions
20.04.2012 / 16:39
---------------------------------------------------------------------
Schlieren (Zurich), Switzerland, April 20, 2012 - Cytos Biotechnology Ltd
(the 'Company') announced that at today's Annual Shareholders' Meeting 2012
the shareholders approved all proposals and hence agreed to the refinancing
and in particular to the announced capital increase and the election of the
additional members of the board of directors. With this approval the main
conditions precedent for the execution of the refinancing are fulfilled and
the Company will thus initiate the necessary steps to conclude the capital
increase as soon as possible.
As the election of Joseph Anderson, Paul Berriman, Paul Brook, Kurt von
Emster and Arthur Krieg as additional members of the Board of Directors is
only legally valid upon registration of the capital increase in the
commercial register, the Board of Directors consists of Dr. Thomas Hecht,
president und Jakob Schlapbach, member, up to then.
The Annual Shareholders' Meeting took place at the premises of the Company
at Schlieren (Zurich), Switzerland. 42 shareholders accepted the
invitation. In total 1,804,146 shares were present or represented
accounting for 31.32% of the total of 5,760,056 shares issued.
As previously announced, existing shareholders have the opportunity to
participate in the capital increase by way of a rights offering of up to
CHF 5 million. The start and term of the subscription period will be
announced in a separate media release.
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel.: +41 44 733 46 46
e-Mail: harry.welten(at)cytos.com
Webpage: www.cytos.com
About Cytos Biotechnology Ltd
Cytos Biotechnology Ltd is a Swiss public biotechnology company that
specializes in the development and commercialization of a new class of
biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM) are
intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce the desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Cytos' Immunodrug(TM) candidates are being developed both
in-house and together with Novartis, Pfizer and Pfizer Animal Health.
Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology
(ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos
Biotechnology Ltd is listed on the main segment of the SIX Swiss Exchange
Ltd under the symbol CYTN.
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The Company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments. This document does not constitute an offer
or invitation to subscribe or purchase any securities of Cytos
Biotechnology Ltd.
End of Corporate News
---------------------------------------------------------------------
20.04.2012 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Open Market in Frankfurt; SIX
End of News EquityStory AG News-Service
---------------------------------------------------------------------
165905 20.04.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2012 - 10:39 Uhr
Sprache: Deutsch
News-ID 1105499
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 87 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Annual Shareholder's Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
